Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Mantle-Cell 5Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Leukemia, B-Cell 2Lymphatic Diseases 1Heart Failure 1

Interventions

Cyclophosphamide 11Biopsy 11Specimen Handling 10Rituximab 9Magnetic Resonance Spectroscopy 9obinutuzumab 6fludarabine 6Prednisone 6Lenalidomide 6pembrolizumab 5Nuclear Medicine Department, Hospital 5X-Rays 4Doxorubicin 4venetoclax 3fludarabine phosphate 3Vincristine 3Tacrolimus 3Mycophenolic Acid 3GSK2636771 3Etoposide 3Busulfan 3Bendamustine Hydrochloride 3trametinib 2tocilizumab 2palbociclib 2osimertinib 2ipatasertib 2ibrutinib 2glofitamab 2erdafitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma × acalabrutinib × 30 days × Clear all
NCT05951959 2026-06-01

TrAVeRse

AstraZeneca

Phase 2 Active not recruiting
108 enrolled
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT05495464 2026-05-20

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
22 enrolled
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡